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Introduction {#sec005}
============

Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) occur approximately 1 in 3.000 to 3.500 live births representing the most common malformation of the upper digestive tract \[[@pone.0234246.ref001]; [@pone.0234246.ref002]; [@pone.0234246.ref003]; [@pone.0234246.ref004]\]. According to the "European network of population-based registries for the epidemiological surveillance of congenital anomalies (EUROCAT) EA/TEF account for 1% of all birth defects in Europe every year (<https://eu-rd-platform.jrc.ec.europa.eu/eurocat>). Hence, with 5.075 million babies born in the EU in 2017, 1.237 babies have been born with EA/TEF.

In about 40--50% of cases, EA/TEF occurs within the context of additional anomalies mostly belonging to the VATER/VACTERL association (OMIM \#192350) spectrum. This acronym refers to the rare, nonrandom co-occurrence of the following component features (CFs): vertebral defects (V), anorectal malformations (A), cardiac defects (C), tracheoesophageal fistula with or without esophageal atresia (TE), renal malformations (R), and limb defects (L) \[[@pone.0234246.ref005]\]. Only half a century ago, EA/TEF was fatal among affected newborns suggesting that the steady birth prevalence might in parts be due to mutational *de novo* events in genes involved in foregut development. Support for this hypothesis comes from early reports of chromosomal *de novo* aberrations present in 6--10% of syndromic EA/TEF cases \[[@pone.0234246.ref006]\]. Furthermore, using copy number variation (CNV) analysis in 375 EA/TEF patients we identified eight rare CNVs in six patients, all of which occurred *de novo*, including one CNV previously associated with EA/TEF \[[@pone.0234246.ref007]\]. Hence, 1.55% of isolated EA/TEF patients and 1.62% of patients with additional congenital anomalies carried *de novo* CNVs. Moreover, several monogenic EA/TEF associated syndromes are caused by smaller *de novo* changes comprising single nucleotides or small indels e.g. *N-MYC* in Feingold syndrome (OMIM \#164280), *GLI2* in Pallister-Hall syndrome (OMIM \#146510), *CHD7* in CHARGE syndrome (OMIM \#214800), and *SOX2* in AEG syndrome (OMIM \#206900) \[[@pone.0234246.ref008]; [@pone.0234246.ref009]; [@pone.0234246.ref010]; [@pone.0234246.ref011]\].

To further explore the involvement of small genetic *de novo* events in the etiology of EA/TEF, we profiled 30 case-parents trios using exome sequencing (ES). Prior to ES chromosomal microarray analysis was negative in all cases \[[@pone.0234246.ref007]; [@pone.0234246.ref012]\]. All confirmed *de novo* variants were prioritized using *in silico* prediction tools. To investigate the embryonic role of genes harboring prioritized *de novo* variants we performed targeted analysis of mouse transcriptome data of esophageal tissue obtained at embryonic day (E) E8.5, E12.5, and postnatal.

Materials and methods {#sec006}
=====================

Patients and DNA isolation {#sec007}
--------------------------

In 2011, the authors JS and HR founded the scientific network "great" (genetic risk for esophageal atresia; [www.great-konsortium.de](http://www.great-konsortium.de/)). The "great network" was founded in order to initiate a nationwide investigation into the genetic causes of EA/TEF. Prior to the commencement of recruitment, the network partners generated a unique standardized case report form (CRF). The CRF comprises an epidemiological questionnaire and a clinical assessment battery. The epidemiological questionnaire is based on: (i) the National Birth Defect Prevention Study questionnaire of the U.S. Centers of Disease Control and Prevention ([www.nbdpn.org](http://www.nbdpn.org/)); and (ii) the questionnaire of the European Surveillance of Congenital Malformations (EUROCAT) network ([www.eurocat-network.eu](http://www.eurocat-network.eu/)). The clinical assessment battery comprises the classification system of the EA/TEF phenotype according to Gross (1953), and the ICD10 coding with the British Pediatric Association one digit extension ([www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf](http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf)) for classification of additional congenital anomalies. The great cohort is being recruited with the support of pediatric surgical departments across Germany, and the German self-help organization for patients and families with EA/TEF (KEKS e.V.; [www.keks.org](http://www.keks.org/)). KEKS e.V. is the largest self-help organization for EA/TEF families in Europe, and supports both the ongoing great investigations and the present proposal.

The here described study fulfilled the requirement of the Declaration of Helsinki and ethical approval was obtained from the local ethic committee of the Medical Faculty of Bonn (Lfd. Nr. 073/12). Every participating family provided written informed consent. The 30 here reported case-parent trios as well as the EA/TEF cohort for resequencing of *ZFHX3*, were recruited through the efforts of the scientific network "great". In 14 of the 30 case-parent trios, EA/TEF occurred isolated/nonsyndromic. In the remaining case-parent trios EA/TEF co-occurred with additional phenotypic features (syndromic cases) mostly belonging to the VATER/VACTERL spectrum ([S1 Table](#pone.0234246.s005){ref-type="supplementary-material"}). From each case-parent trio, EDTA blood samples were obtained. Genomic DNA was isolated using the Chemagic DNA Blood Kit special (Chemagen, Baesweiler, Germany). Through personal communication we identified another patient with EA/TEF as part of his VATER/VACTERL association (patient 750_501).

Exome Sequencing (ES) and data analysis {#sec008}
---------------------------------------

Exome capture was performed using the NimbleGen SeqCap EZ Human Exome Library v2.0 enrichment kit and sequenced with an Illumina paired end 2x100 bp sequencing (protocol v1.2). Primary data was filtered according to signal purity by the Illumina Realtime Analysis (RTA) software v1.8. Subsequently, reads were mapped to the human genome reference build hg19 using the bwa-aln \[[@pone.0234246.ref013]\] alignment algorithm. GATK v1.6 \[[@pone.0234246.ref014]\] was used to mark duplicated reads, for local realignment around short insertions and deletions, to recalibrate the base quality scores and to call SNVs (incorporating variants quality score recalibration) and short indels \[[@pone.0234246.ref015]\]. Scripts developed in-house at the Cologne Center for Genomics (unpublished) were used to incorporate allele frequencies reported by the ESP6500 database \[Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: <http://evs.gs.washington.edu/EVS/>)\] and to detect changes in the protein structure. Acceptor and donor splice site mutations were analyzed with a Maximum Entropy model \[[@pone.0234246.ref016]\]. *De novo* variant calling was performed with the program DeNovoGear (v.0.5.1) \[[@pone.0234246.ref017]\] The Varbank GUI (unpublished, [https://varbank.ccg.uni-koeln.de](https://varbank.ccg.uni-koeln.de/)) was used to filter for high quality (coverage\>15; quality\>25), rare (MAF\<0.005), *de novo* (posterior probability of a *de novo* mutation = PP_DNM\>0.5) variants predicted to alter protein structure or splicing. We also filtered against an in-house database containing all variants from 511 exomes from epilepsy patients to exclude pipeline-related artefacts (MAF\<0.004). Variants with MAF\<0.004 that have been described to occur homozygous in gnomAD were also excluded. Finally, we further excluded all variants with a MAF≥0.0003 since the EA/TEF birth prevalence has been reported to be 1 in 3.500 live births (frequency of ≈ 0.0003). Hence, (full penetrant) monoallelic variants with a MAF≥0.0003 cannot account for the occurrence of EA/TEF.

Variant validation and classification {#sec009}
-------------------------------------

Variants identified by ES were validated by using polymerase chain reaction (PCR). Automated sequence analysis was carried out using standard procedures. In brief, primers were directed to all variants observed and the resultant PCR products were subjected to direct automated BigDye Terminator sequencing (3130XL Genetic Analyzer, AppliedBiosystems, FosterCity, California, USA). Both strands from each amplicon were sequenced for the presence of these variants in the respective case-parent trio. In order to further prioritize the identified and confirmed *de novo* variants, we analyzed them using ten different *in silico* prediction tools which are encountered in dbNSFP v3.0 (<https://sites.google.com/site/jpopgen/dbNSFP>): SIFT, LRT, MutationTaster, Mutation Assessor, FATHMM, PROVEAN, MetaSVM, MetaLR, fathmm-MKL coding and CADD \[[@pone.0234246.ref018]; [@pone.0234246.ref019]\] (details about these prediction tools are given as supporting information [S1 Data](#pone.0234246.s007){ref-type="supplementary-material"}).

Re-sequencing of *ZFHX3* in EA/TEF patients {#sec010}
-------------------------------------------

All three human *ZFHX3* protein coding transcripts (ENST00000641206.2, ENST00000268489.10, and ENST00000397992.5) listed in 'ensembl database' ([www.ensembl.org/](http://www.ensembl.org/) Ensembl Release 98 (September 2019)) were sequenced in 192 unrelated EA/TEF patients. PCR-amplified DNA products (primer sequences available upon request) were subjected to sequencing using a 3130XL Genetic Analyzer (Applied Biosystems, Foster City, USA).

Structural modeling and in-silico analysis of ZFHX3 protein variants {#sec011}
--------------------------------------------------------------------

The secondary structure prediction of human OCTs protein sequences was done using PSIPRED in I-Tasser. Three-dimensional protein structural models for ZFHX3 were built using SWISS-MODEL (<https://swissmodel.expasy.org/>). Since, Swiss model cannot handle large protein sequence, for the prediction of ZFHX3 *de novo* changes p.Pro534Arg and p.Ala2126Val we trimmed the sequence of 60 amino acids upstream and 20 downstream of the mutated site. The sequence was subjected to swiss-model based modeling. The structural comparison between wild-type and mutant variant was done in Chimera after superimposing the structure of mutant onto the wild structure using SuperPose using default parameters (superpose.wishartlab.com).

RNA isolation and mRNA library preparation of mouse embryonic esophageal tissue {#sec012}
-------------------------------------------------------------------------------

All animals used in this study were anesthetized by Isoflurane and killed by cervical dislocation. The animals that were used in this study are documented and their usage reported to the local authorities Regierungspräsidium Darmstadt). Embryos from pregnant females of the C57Bl6J strain were harvested at embryonic days (E) E8.5, E12.5, and postnatal. The embryos of the E8.5 litter were determined to be of the developmental Theiler stage 13 (TS13) and the E12.5 embryos TS21. From E8.5 embryos, the pharyngeal pouch containing endoderm and adjacent mesoderm tissue was surgically isolated and transferred into QIAzol^®^. Multiple embryos were pooled for each embryonal timepoint. For the E8.5 stage we pooled biopsies from 5 embryos to prepare the RNA and for the E12.5 and neonates we pooled two each for RNA preparation. From E12.5 and postnatal embryos, the distinct structures of the esophagus and the trachea was surgically isolated, combined and transferred into QIAzol^®^. RNA was isolated from these tissues with the RNEasy Mini Plus Kit (Qiagen) according to the manufacture's protocols. The transcriptome profile was assessed by RNA-Sequencing with the 3'-mRNASeq Library Preparation Kit from Lexogen, (Lexogen, Vienna, Austria). This protocol generates for each transcript only one single-end strand specific fragment for sequencing at the 3'-end of poly(A)-RNA. Libraries were quality checked on a TapeStation2200 (Agilent, Santa Clara, USA). The sequencing was performed on a HiSeq 2500 (Illumina, San Diego, USA) with two technical replicates of sample.<http://www.bioinformatics.babraham.ac.uk/projects/>

Transcriptome analysis {#sec013}
----------------------

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654802/>After demultiplexing with bcl2fastq (Illumina, San Diego, USA), FastQC v0.11.8 (<http://www.bioinformatics.babraham.ac.uk/projects/>) was used for quality control of FASTQ files. Read alignment was performed using STAR_2.6.1d \[[@pone.0234246.ref020]\] against the primary assembly of murine genome reference build GRCm38 according to the manufacturer's analysis protocol. Read counting was also performed with STAR ("quantMode GeneCounts") using the Ensembl gene annotation (Release 97). Quality metrics were gathered with multiQC \[[@pone.0234246.ref021]\].

Statistical analyses were performed with the programming language R (R Core Team, 2019) and the DESeq2 R package \[[@pone.0234246.ref022]\] Technical replicates where combined and differential gene expression considering the embryonal timepoint was assessed with the DESeq2's Wald test as described in Love et al. \[[@pone.0234246.ref023]\] We required an alpha level of 0.01 and a minimum log2 foldchange of log2(1.5). Cumulative expression distributions were calculated for *rlog* normalized expression values for each timepoint separately. We identified the mouse homologous genes of our human genes of interest using the biomaRt R package \[[@pone.0234246.ref024]\].

Results {#sec014}
=======

ES analysis {#sec015}
-----------

ES analysis identified 25 apparent *de novo* variants in 25 genes in 18 unrelated case-parent trios. Confirmation of these variants using Sanger sequencing validated all of them and confirmed 23 as being *de novo* in patients. 14 of these variants were novel according to the "Genome Aggregation Database (gnomAD; <https://gnomad.broadinstitute.org/>; November 2019)". In addition, eight of the confirmed *de novo* variants were found to be rare with a minor allele frequency (MAF) between 0.000003--0.00003 ([Table 1](#pone.0234246.t001){ref-type="table"}). One confirmed *de novo* variant in *TPP2* (c.1534G\>A, p.Val512Ile, NM_003291.2, rs73578896) has been previously reported in gnomAD with a MAF of 0.002 (303/275.928) and was therefore filtered out. Through personal communication during the project (Dr. Julia Höfele, Institute of Human Genetics, Klinikum Rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany) we identified an additional EA/TEF case-parent trio (750_501) in which the patient carries a rare *de novo* variant in *ZFHX3* (c.6377C\>T, p.Ala2126Val, allele frequency 0.000019) (marked with an asterisks in [Table 1](#pone.0234246.t001){ref-type="table"}).

10.1371/journal.pone.0234246.t001

###### Prioritized *de novo* variants.

![](pone.0234246.t001){#pone.0234246.t001g}

  Ext-Code    Phenotype                                                    Variant       HGNC                   Refseq        gnomAD (MAF)           MutCDNA          MutProt          Mm      Gg      Dr      Xt
  ----------- ------------------------------------------------------------ ------------- ---------------------- ------------- ---------------------- ---------------- ---------------- ------- ------- ------- -------
  4_501       [V]{.ul}A[TE]{.ul}R/[V]{.ul}AC[TE]{.ul}RL-like association   1             *EEF1D*                NM_032378.4                          **c.874C\>T**    **p.Arg292\***   K       E               K
  2           *CELSR1*                                                     NM_014246.1   3/282,594 (0.00001)    c.4357G\>A    p.Val1453Ile           V                I                        I               
  21_501      nonsyndromic                                                 3             *HPS3*                 NM_032383.3   10/282,776 (0.00004)   c.1189C\>T       p.Arg397Trp      H       R       R       R
  27_501      nonsyndromic                                                 4             *PIGC*                 NM_153747.1                          c.716C\>T        p.Ala239Val      A               G       A
  35_501      [V]{.ul}A[TE]{.ul}R/[V]{.ul}AC[TE]{.ul}RL-like association   5             *NFX1*                 NM_002504.4                          c.1723G\>A       p.Val575Met      V                       V
  36_501      nonsyndromic                                                 6             ***ZFHX3***            NM_006885.3                          c.1601C\>G       p.Pro534Arg      P       P       P       N
  41_501      VA[TER]{.ul}/VA[CTER]{.ul}L-like association                 7             *MTA3*                 NM_020744.2   1/237,600 (0.000004)   c.393C\>A        p.Phe131Leu      F               F       
  46_501      nonsyndromic                                                 8             ***FANCB***            NM_152633.2                          c.782G\>A        p.Arg261Gln      R       Q       S       
  9           *PLEC*                                                       NM_201379.1   17/272,690 (0.00006)   c.6704G\>A    p.Arg2394His           R                R                K       R               
  63_501      VA[TE]{.ul}R/VA[CTE]{.ul}RL-like association                 10            *PPIP5K2*              NM_015216.2   2/247,732 (0.000008)   c.686G\>A        p.Arg229Gln      **R**   **R**   **R**   **R**
  88_501      nonsyndromic                                                 11            *CLP1*                 NM_006831.2   1/251,486 (0.000003)   c.814C\>A        p.His272Asn      **H**   **H**   **H**   **H**
  12          *GPR133*                                                     NM_198827.3   6/282,534 (0.00002)    c.1033G\>A    p.Ala345Thr            A                                                         
  13          *SLC5A2*                                                     NM_003041.3                          c.644T\>C     p.Leu215Pro            L                                 L       L               
  90_501      VA[TE]{.ul}R/VA[CTE]{.ul}RL-like association                 14            ***KIAA0556***         NM_015202.2                          c.3730C\>T       p.His1244Tyr     **H**   **H**   **H**   **H**
  141_501     VA[TE]{.ul}R/VA[CTE]{.ul}RL-like association                 15            *STAB1*                NM_015136.2   9/278,948 (0.00003)    c.6145C\>T       p.Arg2049Cys     R               S       
  154_501     V[ATER]{.ul}/V[ACTE]{.ul}RL association                      16            *GGT6*                 NM_153338.2                          c.1045A\>G       p.Ser349Gly      S                       
  167_501     nonsyndromic                                                 17            ***CHD7***             NM_017780.3                          c.4187C\>G       p.Ala1396Gly     A       A       A       
  172_501     VA[TE]{.ul}R/VA[CTE]{.ul}RL-like association                 18            *NPR2*                 NM_003995.3                          c.952C\>G        p.Arg318Gly      R       K               T
  174_501     nonsyndromic                                                 19            *UBA3*                 NM_198195.1                          c.1088C\>T       p.Ser363Phe      S       S       T       P
  181_501     nonsyndromic                                                 20            *TANC2*                NM_025185.3                          c.2357C\>T       p.Pro786Leu      P               P       P
  288_501     VA[TE]{.ul}R/VA[CTER]{.ul}L association                      21            ***TRPS1***            NM_014112.2                          **c.1630C\>T**   **p.Arg544\***   R               R       R
  22          *APOL2*                                                      NM_145637.1                          c.319G\>C     p.Glu107Gln            D                                                         
  750_501\*   V[ATER]{.ul}/V[ACTER]{.ul}L association                      23            ***ZFHX3***            NM_006885.3   5/250,880 (0.00002)    c.6377C\>T       p.Ala2126Val     A       T       T       A

Annotations marked in bold red represent: "known disease genes" involved in the formation of congenital malformations, variants with truncating consequence, variants in highly conserved regions of the protein, or novel variants (not found in (n.f.i.), gnomAD (MAF)).

Among the novel variants (i) five reside within previously described disease genes (*CHD7*, *FANCB*, *TRPS1*, *KIAA0556*, and *ZFHX3*), (ii) two variants were truncating (c.874C\>T (p.Arg292\*) in *EEF1D* and c.1630C\>T (p.Arg544\*) in *TRPS1*), and (iii) three amino acid changes (p.Arg229Gln in *PPIP5K2;* p.His272Asn in *CLP1*; p.His1244Ytyr in *KIAA0556*) reside in highly conserved regions of the respective protein ([Table 1](#pone.0234246.t001){ref-type="table"}). Of the novel *de novo* variants constituting missense variants four amino acid changes (p.Pro534Arg in *ZFHX3*; p.Phe131Leu in *MTA3*; p.Leu215Pro in *SLC5A2*; p.Ala1396Gly in *CHD7*) were called deleterious by at least seven out of nine *in silico* prediction tools (written in bold in [Table 2](#pone.0234246.t002){ref-type="table"}). Similarly, the rare *de novo* variant in *ZFHX3* (c.6377C\>T, p.Ala2126Val, allele frequency 0.000019) found in the additional case-parent trio (750_501), was also called deleterious by seven out of nine *in silico* prediction tools (written in bold in [Table 2](#pone.0234246.t002){ref-type="table"}).

10.1371/journal.pone.0234246.t002

###### Classification of *de novo* variants using in silico prediction programs.

![](pone.0234246.t002){#pone.0234246.t002g}

  Ext-Code                                       Variant    HGNC         MutCDNA                gnomAD (MAF)           SIFT    LRT     Mutation Taster   Mutation Assessor   FATHMM   PROVEAN   Meta SVM   Meta LR   Fathmm MKL_coding   CADD Score
  ---------------------------------------------- ---------- ------------ ---------------------- ---------------------- ------- ------- ----------------- ------------------- -------- --------- ---------- --------- ------------------- ------------
  4_501                                          1          *EEF1D*      c.874C\>T                                     \-      N       A                 \-                  \-       \-        \-         \-        N                   **28,5**
  2                                              *CELSR1*   c.4357G\>A   3/282,594 (0.00001)    T                      U       N       N                 T                   N        T         T          D         15,3                
  21_501                                         3          *HPS3*       c.1189C\>T             10/282,776 (0.00004)   D       D       A                 M                   T        D         D          T         D                   **35**
  27_501                                         4          *PIGC*       c.716C\>T                                     T       D       D                 M                   T        N         T          T         D                   11,6
  35_501                                         5          *NFX1*       c.1723G\>A                                    D       N       N                 L                   T        N         T          T         D                   **20,8**
  36_501                                         6          *ZFHX3*      c.1601C\>G                                    D       N       D                 L                   T        N         T          T         D                   **22,3**
  41_501                                         7          *MTA3*       c.393C\>A              1/237,600 (0.000004)   **D**   **D**   **D**             H                   **D**    **D**     **D**      **D**     **D**               **26**
  46_501                                         8          *FANCB*      c.782G\>A                                     T       N       N                 N                   T        N         T          T         N                   7,2
  9                                              *PLEC*     c.6704G\>A   17/272,690 (0.00006)   D                      U       D       N                 T                   N        T         T          D         **26,5**            
  63_501                                         10         *PPIP5K2*    c.686G\>A              2/247,732 (0.000008)   D       D       D                 M                   T        D         T          T         D                   **34**
  88_501                                         11         *CLP1*       c.814C\>A              1/251,486 (0.000003)   T       D       D                 L                   T        N         T          T         D                   17,4
  12                                             *GPR133*   c.1033G\>A   6/282,534 (0.00002)    T                      N       N       N                 T                   N        T         T          N         0,016               
  13                                             *SLC5A2*   c.644T\>C                           **D**                  **D**   **D**   H                 **D**               **D**    **D**     **D**      **D**     **27,6**            
  90_501                                         14         *KIAA0556*   c.3730C\>T                                    D       N       N                 L                   T        N         T          T         N                   1,9
  141_501                                        15         *STAB1*      c.6145C\>T             9/278,948 (0.00003)    T       N       N                 M                   T        D         T          T         N                   **24,1**
  154_501                                        16         *GGT6*       c.1045A\>G                                    D       N       N                 N                   T        D         T          T         N                   5,9
  167_501                                        17         *CHD7*       c.4187C\>G                                    **D**   **D**   **D**             H                   T        **D**     **D**      **D**     **D**               **33**
  172_501                                        18         *NPR2*       c.952C\>G                                     T       N       D                 L                   D        D         T          T         D                   **22,2**
  174_501                                        19         *UBA3*       c.1088C\>T                                    D       D       D                 L                   T        D         T          T         D                   **27,8**
  181_501                                        20         *TANC2*      c.2357C\>T                                    T       D       D                 L                   T        D         T          T         D                   **22,7**
  288_501                                        21         *TRPS1*      c.1630C\>T                                    \-      D       A                 \-                  \-       \-        \-         \-        D                   **36**
  22                                             *APOL2*    c.319G\>C                           T                      N       N       N                 T                   N        T         T          N         0,004               
  750_501[\*](#t002fn001){ref-type="table-fn"}   23         *ZFHX3*      c.6377C\>T             5/250,880 (0.00002)    **D**   **D**   **D**             L                   T        **D**     **D**      **D**     **D**               19,2

\*A: automatic disease causing; D: disease causing; H: high functional; L: non-functional; M: medium functional; N: neutral; T: tolerant. Annotations marked in bold red represent: "variants that are classified to be disease causing by at least eight out of ten *in silico* prediction programs (except for truncating variants) used by dbNSFP v3.0 (<https://sites.google.com/site/jpopgen/dbNSFP>)".

One of the novel *de novo* variants (*PIGC*, c.716C\>T, CADD score 11,6) and three of the rare *de novo* variants (*CELSR1*, c.4357G\>A, CADD score 15.3; *CLP1*, c.814C\>A, CADD score 17.4; *ZFHX3*, c.6377C\>T, CADD score 19.2) reached CADD scores between 10 and 20 indicating that these variants have been predicted to be among the 10% most deleterious substitutions within the human genome. Nine of the novel *de novo* variants (*EEF1D*, c.874C\>T, CADD score 28.5; *NFX1*, c.1723G\>A, CADD score 20.8; *ZFHX3*, c.1601C\>G, CADD score 22.3; *SLC5A2*, c.644T\>C, CADD score 27.6; *CHD7*, c.4187C\>G, CADD score 33; *NPR2*, c.952C\>G, *CADD* score 22.2, *UBA3*, c.1088C\>T, CADD score 27.8, *TANC2*, c.2357C\>T, CADD score 22.7; *TRPS1*, c.1630C\>T, CADD score 36) and five of the rare *de novo* variants (*HPS3*, c.1189C\>T, CADD score 35; MTA3, c.393C\>A, CADD score 26; *PLEC*, c.6704G\>A, CADD score 26.5; *PPIP5K2*, c.686G\>A, CADD score 34; *STAB1*, c.6145C\>T, CADD score 24.1) reached CADD scores over 20 indicating that these variants are predicted to be among the 1% most deleterious variants in the human genome (written in bold in [Table 2](#pone.0234246.t002){ref-type="table"}).

Re-sequencing of *ZFHX3* in EA/TEF patients {#sec016}
-------------------------------------------

Re-sequencing of *ZFHX3* in 192 EA/TEF patients did not identify additional putative disease-causing variants.

Structural modeling and in-silico analysis of ZFHX3 protein variants {#sec017}
--------------------------------------------------------------------

Swiss model employed template id 3wbj.1.A as a template and built the ZFHX3 amino acid change p.Pro534Arg. Structural models were obtained with sequence identity 14.89%, coverage of 58.75%, and normalized Z-score of -2.90. The respective values are considered as an indicative of correctly folded and good modeled structures close to native structure. For the amino acid change p.Ala2126Val, structural models were obtained with sequence identity of 19.15%, coverage 27.48%, and normalized Z-score of -1.76. From the structural modeling of the ZFHX3 amino acid changes, we found that the two changes do not have any distortion in the native protein amounting to RMSD change at α-carbon is 0.02 Å and at backbone is 0.03 Å in p.Pro534Arg and RMSD change of at α-carbon is 0.05 Å and at backbone is 0.06 Å in p.AlaA2126Val ([S1](#pone.0234246.s001){ref-type="supplementary-material"}--[S4](#pone.0234246.s004){ref-type="supplementary-material"} Figs).

Transcriptome analysis {#sec018}
----------------------

Evaluation of the transcriptome data showed that all murine genes were expressed at E8.5, E12.5, and postnatal except for some *APOL2* orthologous. Differential gene expression analysis revealed that four out of 24 genes were transcriptome-wide differentially expressed between the time points of E8.5 and E12.5 (*Chd7*: logFC 2.243, p.adj 1.85E-29; *Npr2*: logFC -2.268, p.adj 5.18E-04; *Trps1*: logFC -2.927, p.adj 1.17E-28; *Eef1d*: logFC 1.248, p.adj 6.41E-05), and two between the time points E12.5 and postnatal (*Apol7a*: logFC -9.273, p.adj 5.18E-07; *Plec*: logFC -2.352, p.adj 9.09E-24). Interestingly, most of the candidate genes were highly expressed at each time point ([Fig 1](#pone.0234246.g001){ref-type="fig"}, [Fig 2](#pone.0234246.g002){ref-type="fig"}, [S2 Table](#pone.0234246.s006){ref-type="supplementary-material"}). The candidate genes *Zfhx3*, *Ppip5k2*, *Chd7* and *Eef1d* were even expressed above the 95^th^ percentile at E8.5 compared to the expression of all other genes. In addition, the genes *Ppip5k2*, *Trps1*, *Zfhx3* and *Eef1d* were expressed above the 93^rd^ percentile at E12.5.

![Empirical cumulative distribution of murine candidate gene expression at each timepoint.\
The empirical cumulative distribution function (F) was calculated from Regularized Log (*rlog)* transformed expression values. E: embryonic day.](pone.0234246.g001){#pone.0234246.g001}

![Murine candidate gene expression at three different timepoints.\
The gene expression is shown as log2 expression on the y-axis, while the timepoint is shown as categorial variable on the x-axis. The header of each sub figure shows the murine and human gene symbols. E: embryonic day, pn: postnatal.](pone.0234246.g002){#pone.0234246.g002}

Discussion {#sec019}
==========

The etiology of EA/TEF is heterogeneous. Previously, disease causing monoallelic mutations of variable genomic size have been reported among EA/TEF patients \[[@pone.0234246.ref007]; [@pone.0234246.ref025]\] Here, we identified 23 single nucleotide *de novo* variants in 23 different genes using 30 unrelated case-parent trios and ES. All confirmed *de novo* variants were prioritized using *in silico* prediction tools. The embryonic role of genes harboring prioritized *de novo* variants was further investigated by targeted analysis of mouse transcriptome data of esophageal tissue obtained at E8.5, E12.5, and postnatal.

After prioritization of variants using *in silico* prediction tools, targeted analysis of mouse transcriptome data, and review of the literature we prioritize *TRPS1* and *ZFHX3* as new EA/TEF candidate genes and provide further support for *CHD7* as a key player in esophageal development.

The identified *de novo* amino acid change in *CHD7* has not been previously described. *CHD7* has been established as the major disease gene for CHARGE syndrome (OMIM \#214800) \[[@pone.0234246.ref026]\]. Eight out of nine *in silico* prediction programs used by dbNSFP v3.0 (<https://sites.google.com/site/jpopgen/dbNSFP>) classified this *de novo* amino acid change p. Ala1396Gly in *CHD7* as deleterious. As about 20% of patients with CHARGE syndrome present with EA/TEF \[[@pone.0234246.ref027]\] we consider the identified variant as disease causing in our patient (167_501, [Table 1](#pone.0234246.t001){ref-type="table"}) even though patient 167_501 did not present with additional congenital anomalies besides EA/TEF that would have suggested the clinical diagnosis of CHARGE syndrome. None of the other identified *de novo* variants resided within a gene that was previously linked to the formation of EA/TEF.

In patient 288_501 we identified a novel *de novo* truncating amino acid change p.Arg544\* in *TRPS1* associated with tricho-rhino-phalangeal syndrome I (OMIM \#190350). Previously Maas et al. (2015) reported the same truncating variant in three unrelated patients with TRPS1 \[[@pone.0234246.ref025]\]. Unlike our patient 288_501, these previously reported patients did not present with any congenital anomaly of esophagus or trachea nor with any congenital anomaly of the heart (personal communication with Dr. Raoul C. Hennekam). Interestingly, in the here generated expression data *Trps1* shows a consistently high expression levels of 67^th^ percentile at E8.5 and a log2 Foldchange of -2.92 between days E8.5 and E12.5 in mouse embryos in the esophageal area, suggestive of an involvement of Trps1 during vertebrate foregut development. The latter hypothesis suggests that the here identified *de novo* variant in *TRPS1* might be involved in the expression of EA/TEF in patient 288_501.

In patient 36_501 with nonsyndromic EA/TEF we identified a novel *de novo* variant in *ZFHX3*. Through personal communication during the project we identified another patient with EA/TEF as part of his VATER/VACTERL association (patient 750_501) with a *de novo* variant in *ZFHX3*. While the novel variant p.Pro534Arg resides in a well-conserved region of *ZFHX3* and has not been reported in gnomAD, the variant p.Ala2126Val has been reported five times heterozygous in 250,880 alleles in gnomAD (MAF 0.00002) ([Table 1](#pone.0234246.t001){ref-type="table"}) and resides in a less well conserved region of *ZFHX3*. Prompted by this finding, we re-sequenced *ZFHX3* in 192 additional EA/TEF patients but did not find any further putative EA/TEF associated variant. In order to further analyze the two identified amino acid changes in ZFHX3 we further performed structural modeling and *in-silico* analysis of ZFHX3 protein. Here, substitution of C to G at position c.1601 has resulted in substitution of Pro to Arg at position 534 with a RMSD value amounting to 0.02Å at C-alpha carbon and 0.03Å in the protein backbone. Similarly, for the C to T substitution at c.6377 position that resulted into Ala to Val substitution at position 2126 has also recorded a similar change in RMSD value, 0.05Å at C-alpha carbon and 0.06Å in the protein backbone. While the structural modeling suggests that both changes do not cause distortion of the native protein, a possible functional impact of both variants would warrant further functional testing. According to our transcriptome analysis *Zfhx3* is not differentially expressed between either E8.5 and E12.5 or E12.5 and postnatal. However, *Zfhx3* is among the top expressed genes at E8.5 (\>95^th^ percentile) and E12.5 (\>97^rd^ percentile). Interestingly, Thisse and Thisse (2004) reported also expression of *zfhx3* in zebrafish larvae 24 hours post fertilization in the region of the pharyngeal arches representing a series of paired bony or cartilaginous arches that develop along the lateral walls of the foregut, supporting the role of *ZFHX3* in vertebrate foregut development \[[@pone.0234246.ref028]\]. Taken together, the here detected *de novo* variants in human EA/TEF patients, the high *Zfhx3* expression at 8.5 and 12.5 in embryonic foregut tissue of mouse embryos and the previously reported expression of z*fhx3* in zebrafish larvae in the region of the pharyngeal arches suggests *ZFHX3* as a putative EA/TEF candidate gene.

Overall, interpretation of the data is limited by the lack of animal models, at least for the findings in *CHD7*, *TRPS1*, and *ZFHX3*. To the best of our knowledge, there has no animal model been described that would have investigated embryonic foregut development, when these genes have been deleted. In order to definitely conclude that our findings respectively *de novo* variants in *CHD7*, *TRPS1*, and *ZFHX3* have been directly causative for the EA/TEF phenotype in the respective patients, *in vivo* experiments including animal models would be necessary, which were beyond the scope of our present study.

Conclusion {#sec020}
==========

In summary, we detected 23 *de novo* mutations in 23 genes in 17 unrelated patients. Human exome and mouse embryonic expression analyses suggest *ZHFX3* and *TRPS1* as putative EA/TEF candidate genes and endorse *CHD7* as a key player for esophageal development.

Supporting information {#sec021}
======================

###### Wild and mutant structures of ZFHX3 (c.1601C\>G).

(PNG)

###### 

Click here for additional data file.

###### Super imposed structure of ZFHX3 Wild & mutant (c.1601C\>G).
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Click here for additional data file.

###### Wild and mutant structures of ZFHX3 (c.6377C\>T).
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Click here for additional data file.

###### Super imposed structure of ZFHX3 Wild & mutant (c.6377C\>T).

(PNG)
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Click here for additional data file.

###### Phenotypes of the patients included in the ES.

VATER/VACTERL-like association (vertebral defects (V), anorectal malformations (A), cardiac defects (C), tracheoesophageal fistula with or without esophageal atresia (TE), renal malformations (R), and limb defects (L) \[[@pone.0234246.ref005]\], Ventricular septal defect (VSD), atrial septal defect (ASD).

(DOCX)

###### 

Click here for additional data file.

###### logFC: log2 of foldchange, baseMean: Average gene expression across all timepoints, pvalue: nominal P-value, padj: Benjamini-Hochberg corrected P-value, ECDF percentile: Percentile of empirical cumulative distribution function for each timepoint.
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Click here for additional data file.

###### 

(DOCX)

###### 

Click here for additional data file.
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Reviewer \#1: The present study examined the exome of EA/TEF patients and parents (30 trios) aiming at identifying mutational de novo events and the variant forms were prioritized using prediction tools. Then, the embryonic role of the genes with prioritized de novo variants was examined in oesophageal tissue of mice obtained at E8.5, E12.5 and after birth by targeted analysis of the transcriptome.

A total of 14 novel de novo variants in 14 genes and 8 rare de novo variants in another 8 genes were identified. After comparative analysis of the transcriptome of the mouse tissue the authors conclude that CHD7, TRPS1, and ZFHX3 are EA/TEF candidate genes. The conclusion is that rare mutational de novo events involved in foregut embryogenesis contribute to the development of EA/TEF.

The study is well planned and well executed. The collaborative effort to obtain material from a large number of patient/parent trios of this relatively rare disease from several locations is to be commended and the idea of contrasting the findings with mice tissue is an interesting approach.

The introduction is good. M&M are clearly described. The results are well displayed in text and tables and figures. The discussion is OK and the conclusions are sound. The references, figures and tables are OK.

I think that this material deserves publication but, prior to it, I would like to have some additional information and suggest a minor change in the text.

1\. Normal mouse material from E8.5 to E12.5 involves the entire tracheoesophageal cleavage period during which, in case of certain disturbances, EA/TEF is generated. However, at E8.5 there is no oesophagus as such but rather a common foregut tube. In contrast, at day 12.5 the oesophagus is completely separated. It would be useful to have some more details of how microdissection of the material of the foregut and surrounding mesenchyme was made and what part was investigated. The interaction of several genes and transcription factors at epithelial and mesenchymal levels play a role in tracheoesophageal separation. Did samples on E8.5 include the surrounding mesenchyme?. Did samples on E12.5 include the trachea?. EA/TEF is a digestive and respiratory malformation and omitting the respiratory material could lead to incorrect interpretation. Some more details would be appreciated.

2\. According to the authors, the mice were sacrificed by cervical \"translocation\" (to put something at another location). The right word, I believe is \"dislocation\".

Reviewer \#2: The manuscript titled "Human exome and mouse embryonic expression data implicate ZFHX3, TRPS1, and CHD7in human esophageal atresia" is a very interesting study of new insight into pathogenesis of esophageal atresia in human.

Esophageal atresia (OA) and tracheoesophageal fistula (TOF) are relatively frequently occurring foregut malformations whose etiology and pathogenesis are heterogeneous and not clearly understood. Advances in surgical techniques and perioperative care have increased survival rates to over 95% for isolated cases.

The pathogenesis of esophageal atresia is heterogeneous. It is thought that a combination of genetic and environmental factors play a role in the etiology of foregut anomalies and it is most likely. However, recent results from molecular genetic studies on esophageal atresia have yielded a greater understanding of the molecular mechanism involved foregut morphogenesis.

Study of OA patients using trio exome sequencing (patient and parents) associated with the study with mouse transcriptome data of esophageal tissue, are very important step in identifying and understanding etiological factor for this congenital defect.

The study have very well scientific plan and was well performed. The abstract, background and methods sections are clearly written. The result and discussion section is also are very clearly presented.

I have neither major nor minor comments.

Reviewer \#3: This is an interesting paper which aims to find out genes involved in the development of esophageal atresia tracheo esophageal fistula.

The authors recruited 30 trios and performed exome sequencing, in silico testing of the function of proteins resulting from their genetic analysis and tried to validate their finding by looking at differential expression of genes in mice anterior foregut endoderm at E8.5 (just before separation into esophagus and trachea) and at E12.5 (after separation).

Although interesting, the study, essentially descriptive, does not bring significant new information except hypothetic genes which could be involved in EA/TEF. I would suggest to use animal models (zebrafish?) to bring mechanistic data to definitely show the roles of those genes.

Specific questions:

1- How were recruited the 30 trios?

2-How many mouse embryos were pooled for RNA seq? What does mean \'two biological samples were obtained for each time point\'?
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We thank the reviewers for their constructive comments. Following the comments, we have addressed all points and our point-by-point responses are provided below. In each case, we indicate where and how the manuscript has been amended. In the revised manuscript, all changes to the original text are written in red. Previous phrasings have been crossed out. We hope that our manuscript will now be considered suitable for publication.

Reviewer \#1:

The present study examined the exome of EA/TEF patients and parents (30 trios) aiming at identifying mutational de novo events and the variant forms were prioritized using prediction tools. Then, the embryonic role of the genes with prioritized de novo variants was examined in oesophageal tissue of mice obtained at E8.5, E12.5 and after birth by targeted analysis of the transcriptome. A total of 14 novel de novo variants in 14 genes and 8 rare de novo variants in another 8 genes were identified. After comparative analysis of the transcriptome of the mouse tissue the authors conclude that CHD7, TRPS1, and ZFHX3 are EA/TEF candidate genes. The conclusion is that rare mutational de novo events involved in foregut embryogenesis contribute to the development of EA/TEF. The study is well planned and well executed. The collaborative effort to obtain material from a large number of patient/parent trios of this relatively rare disease from several locations is to be commended and the idea of contrasting the findings with mice tissue is an interesting approach. The introduction is good. M&M are clearly described. The results are well displayed in text and tables and figures. The discussion is OK and the conclusions are sound. The references, figures and tables are OK. I think that this material deserves publication but, prior to it, I would like to have some additional information and suggest a minor change in the text.

Comment 1:

Normal mouse material from E8.5 to E12.5 involves the entire tracheoesophageal cleavage period during which, in case of certain disturbances, EA/TEF is generated. However, at E8.5 there is no oesophagus as such but rather a common foregut tube. In contrast, at day 12.5 the oesophagus is completely separated. It would be useful to have some more details of how microdissection of the material of the foregut and surrounding mesenchyme was made and what part was investigated. The interaction of several genes and transcription factors at epithelial and mesenchymal levels play a role in tracheoesophageal separation. Did samples on E8.5 include the surrounding mesenchyme?. Did samples on E12.5 include the trachea?. EA/TEF is a digestive and respiratory malformation and omitting the respiratory material could lead to incorrect interpretation. Some more details would be appreciated.

Answer to Comment 1:

Wie thank the reviewer for this comment. We looked carefully again at the section of the manuscript where we provide the information reviewer \#1 is referring to. In the materials and methods section, we state for the E8.5 timepoint: "the pharyngeal pouch containing endoderm and adjacent mesoderm tissue was surgically isolated". We think this explains very well what part we dissected. For the E12.5 and neonatal timepoint we state: "the distinct structure of the esophagus was surgically isolated and transferred into QIAzol®".

The latter contained an error, which we corrected, and it now reads: "...the distinct structures of the esophagus and the trachea was surgically isolated, combined and transferred into QIAzol®".

Comment 2:

According to the authors, the mice were sacrificed by cervical \"translocation\" (to put something at another location). The right word, I believe is \"dislocation\".

Answer to Comment 2:

We apologize for this autocorrect issue and now corrected the word "translocation" with "dislocation".

Reviewer \#2:

The manuscript titled "Human exome and mouse embryonic expression data implicate ZFHX3, TRPS1, and CHD7in human esophageal atresia" is a very interesting study of new insight into pathogenesis of esophageal atresia in human. Esophageal atresia (OA) and tracheoesophageal fistula (TOF) are relatively frequently occurring foregut malformations whose etiology and pathogenesis are heterogeneous and not clearly understood. Advances in surgical techniques and perioperative care have increased survival rates to over 95% for isolated cases. The pathogenesis of esophageal atresia is heterogeneous. It is thought that a combination of genetic and environmental factors play a role in the etiology of foregut anomalies and it is most likely. However, recent results from molecular genetic studies on esophageal atresia have yielded a greater understanding of the molecular mechanism involved foregut morphogenesis. Study of OA patients using trio exome sequencing (patient and parents) associated with the study with mouse transcriptome data of esophageal tissue, are very important step in identifying and understanding etiological factor for this congenital defect. The study have very well scientific plan and was well performed. The abstract, background and methods sections are clearly written. The result and discussion section is also are very clearly presented. I have neither major nor minor comments.

Comment to the Reviewer:

We thank the reviewer for his decent commentary on our study.

Reviewer \#3:

This is an interesting paper which aims to find out genes involved in the development of esophageal atresia tracheo esophageal fistula. The authors recruited 30 trios and performed exome sequencing, in silico testing of the function of proteins resulting from their genetic analysis and tried to validate their finding by looking at differential expression of genes in mice anterior foregut endoderm at E8.5 (just before separation into esophagus and trachea) and at E12.5 (after separation). Although interesting, the study, essentially descriptive, does not bring significant new information except hypothetic genes which could be involved in EA/TEF. I would suggest to use animal models (zebrafish?) to bring mechanistic data to definitely show the roles of those genes. Specific questions:

Comment 1:

How were recruited the 30 trios?

Answer to Comment 1:

As requested by the reviewer, we have added additional information to how the 30 case-parent trios were recruited. It now reads: "In 2011, the authors JS and HR founded the scientific network "great" (genetic risk for esophageal atresia; www.great-konsortium.de). The "great network" was founded in order to initiate a nationwide investigation into the genetic causes of EA/TEF. Prior to the commencement of recruitment, the network partners generated a unique standardized case report form (CRF). The CRF comprises an epidemiological questionnaire and a clinical assessment battery. The epidemiological questionnaire is based on: (i) the National Birth Defect Prevention Study questionnaire of the U.S. Centers of Disease Control and Prevention ([www.nbdpn.org](http://www.nbdpn.org)); and (ii) the questionnaire of the European Surveillance of Congenital Malformations (EUROCAT) network ([www.eurocat-network.eu](http://www.eurocat-network.eu)). The clinical assessment battery comprises the classification system of the EA/TEF phenotype according to Gross (1953), and the ICD10 coding with the British Pediatric Association one digit extension ([www.eurocat-network.eu](http://www.eurocat-network.eu)/content/EUROCAT-Guide-1.3.pdf) for classification of additional congenital anomalies. The great cohort is being recruited with the support of pediatric surgical departments across Germany, and the German self-help organization for patients and families with EA/TEF (KEKS e.V.; [www.keks.org](http://www.keks.org)). KEKS e.V. is the largest self-help organization for EA/TEF families in Europe, and supports both the ongoing great investigations and the present proposal.

The here described study fulfilled the requirement of the Declaration of Helsinki and ethical approval was obtained from the local ethic committee of the Medical Faculty of Bonn (Lfd. Nr. 073/12). Every participating family provided written informed consent. The 30 here reported case-parent trios as well as the EA/TEF cohort for resequencing of ZFHX3, were recruited through the efforts of the scientific network "great". In 14 of the 30 case-parent trios, EA/TEF occurred isolated/nonsyndromic. In the remaining case-parent trios EA/TEF co-occurred with additional phenotypic features (syndromic cases) mostly belonging to the VATER/VACTERL spectrum (S1 Tbl.). From each case-parent trio, EDTA blood samples were obtained. Genomic DNA was isolated using the Chemagic DNA Blood Kit special (Chemagen, Baesweiler, Germany). Through personal communication we identified another patient with EA/TEF as part of his VATER/VACTERL association (patient 750_501, see Table 1, marked with asterisk)."

Comment 2:

How many mouse embryos were pooled for RNA seq? What does mean \'two biological samples were obtained for each time point\'?

Answer to Comment 2:

We additional information with the following sentence, it now reads: "For the E8.5 stage we pooled biopsies from 5 embryos to prepare the RNA and for the E12.5 and neonates we pooled two each for RNA preparation."
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We thank the reviewer for his comments. We have addressed this comment below. In the revised manuscript, all changes to the earlier revised version are written in red. We hope that our manuscript will now be considered suitable for publication.

Reviewer \#3:

Comment:

Again, the paper would have been stronger with a mechanistic demonstration of the roles of the genes reported as involved in the development of the foregut.

Answer to Comment 1:

We agree with the reviewer that any molecular genetic finding detected in human individuals with congenital malformations should in the following workup of these findings warrant in vivo functional studies, e.g. animal models to provide further evidence for the involvement of the identified molecular genetic findings in the expression of the disease. However, the creation of animal models was beyond the scope of the present study. In order to provide some level of functional evidence, we generated mouse transcriptome data from wildtype mice, in order to see, if the identified potential disease genes are actually expressed during the embryonic critical time frame. Here we were able to show, that Zfhx3 is continuously high expressed during all time points, and that CHD7 and Trps1 are differentially expressed over all three time points.

To address the concern of the reviewer, we have added the following sentence to the end of the discussion: "Overall, interpretation of the data is limited by the lack of animal models, at least for the findings in CHD7, TRPS1, and ZFHX3. To the best of our knowledge, there has no animal model been described that would have investigated embryonic foregut development, when these genes have been deleted. In order to definitely conclude that our findings respectively de novo variants in CHD7, TRPS1, and ZFHX3 have been directly causative for the EA/TEF phenotype in the respective patients, in vivo experiments including animal models would be necessary, which were beyond the scope of our present study."
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Dear Dr. Reutter,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Dear Dr. Reutter:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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